uploads/2018/08/Tecentriq.png

Tecentriq Could Boost Roche’s Revenue Growth in 2018 and Beyond

By

Updated

Revenue trends

Roche’s (RHHBY) Tecentriq generated revenues of 320.0 million Swiss francs in the first half compared to 237.0 million Swiss francs in the first half of 2017, reflecting ~37.0% YoY (year-over-year) growth at CER (constant currency rates).

In the first half, in the United States, Europe, and Japan, Tecentriq generated revenues of 219.0 million Swiss francs, 60.0 million Swiss francs, and 15.0 million Swiss francs, respectively. In the United States, Tecentriq witnessed an ~2.0% YoY decline at CER.

Article continues below advertisement

Tecentriq reported revenues of 181.0 million Swiss francs in the second quarter, which reflected ~44.0% YoY growth at CER. In the United States, Europe, and Japan, Tecentriq reported revenues of 112.0 million Swiss francs, 37.0 million Swiss francs, and 15.0 million Swiss francs, respectively, in the second quarter.

Recent developments

In July, the FDA awarded Tecentriq and Avastin combination therapy a breakthrough therapy designation (or BTD) as first-line therapy for the treatment of individuals with advanced hepatocellular carcinoma (or HCC).

The FDA’s BTD for Tecentriq and Avastin combination therapy for the treatment of advanced HCC was based on the data from the Phase 1b trial. Roche presented this trial at the Annual Meeting of ASCO (American Society of Clinical Oncology) held in June.

In July, Roche announced that its Phase 3 IMpower132 trial met the co-primary endpoints of PFS (Progression-Free Survival). In the Phase 3 IMpower132 trial, Tecentriq and chemotherapy combination demonstrated a reduction in the risk of disease worsening or death in the first-line setting. This compared to chemotherapy for the treatment of individuals with advanced non-squamous non-small cell lung cancer (or NSCLC).

Roche is conducting a various clinical trial for label expansion of Tecentriq. The approval of label expansion of Tecentriq could significantly boost the drug’s revenue growth.

Among Tecentriq’s peers in the NSCLC drugs market, Eli Lilly’s (LLY) Alimta and Cyramza reported second-quarter revenues of $499.6 million and $183.6 million, respectively. AstraZeneca’s (AZN) Tagrisso reported second-quarter revenues of $760.0 million.

Advertisement

More From Market Realist